Skip to main content

Table 1 Characteristics of patients with ovarian cancer and comparison with pretreatment HE4 and CA125 level

From: Early clearance of serum HE4 and CA125 in predicting platinum sensitivity and prognosis in epithelial ovarian cancer

Characteristics Pretreatment HE4 Mean (range) [pmol/L] Pretreatment CA125 Mean (range) [U/ml]
Menopausal
 Premenopausal, n=35 408.8 (32.4–1529) 939.3 (9.0–5023)
 Postmenopausal, n=54 548.7 (47.4–4703) 855.4 (8.0–4423)
P value 0.309 0.733
FIGO stage
 I and II, n=37 286.7 (32.4–1500) 543.8 (8.0–3066)
 III and IV, n=52 641.0 (63.11–4703) 1133.5 (18.8–5023)
P value 0.008 0.008
Tumor grade
 1, n=11 141.2 (33.6–437) 472.0 (9.0–2062)
 2 and 3, n=78 543.4 (32.4–4703) 947.1 (683.6–1210)
P value 0.000 0.191
Histology
 Serous, n=48 618.5 (47.4–4703) 1152.6 (8.0–5023)
 Mucinous, n=7 232.5 (40.8–1132) 139.7 (12.5–523)
 Clear cell, n=11 193.9 (32.4–675) 229.4 (13.0–653)
 Endometrioid, n=8 635.7 (33.6–1529) 714.9 (9.0–1974)
 Others, n=15 360.2 (81.4–1234) 967.9 (11.68–3643)
P value 0.153 0.040
Platinum response
 Sensitive, n=73 487.9 (32.4–4703) 955.2 (8.0–5023)
 Resistant, n=16 520.2 (63.11–1500) 583.5 (15.6–2880)
P value 0.854 0.233
Two-year PFS
 YES, n=59 389.7 (32.4–2106) 898.6 (7.98–5023)
 NO, n=30 698.1 (63.11–4703) 868.2 (15.6–3643)
P value 0.076 0.905